Investors

2014 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle Download Print
12/22/14BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015Download PDFPrinter Friendly Version
12/15/14BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist OfficeDownload PDFPrinter Friendly Version
11/13/14BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate UpdateDownload PDFPrinter Friendly Version
11/05/14BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13Download PDFPrinter Friendly Version
10/07/14FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALSDownload PDFPrinter Friendly Version
10/06/14BrainStorm Reports Last Patient Visit in Phase 2a ALS StudyDownload PDFPrinter Friendly Version
09/30/14BrainStorm Completes Uplisting to the NASDAQ Capital MarketDownload PDFPrinter Friendly Version
09/24/14BrainStorm Receives Approval for Uplisting to the NASDAQ Capital Market Expect Trading to Commence September 30, 2014Download PDFPrinter Friendly Version
09/09/14BrainStorm Provides Update on NASDAQ Uplisting ProcessDownload PDFPrinter Friendly Version
09/04/14BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment ConferenceDownload PDFPrinter Friendly Version
09/03/14BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS DiseasesDownload PDFPrinter Friendly Version
08/18/14FDA Clears Mayo Clinic for Manufacture of NurOwn and Participation in BrainStorm’s Phase 2 ALS TrialDownload PDFPrinter Friendly Version
07/28/14BrainStorm Receives Notice of Allowance on US PatentDownload PDFPrinter Friendly Version
07/15/14BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical TrialDownload PDFPrinter Friendly Version
07/11/14BrainStorm Announces Publication of Preclinical Multidose Study of NurOwnDownload PDFPrinter Friendly Version
06/27/14BrainStorm and Octane Successfully Construct a Bioreactor Prototype For Industrial-Scale Manufacturing of NurOwn Stem CellsDownload PDFPrinter Friendly Version
06/13/14Brainstorm Cell Therapeutics Raises $10.5 Million in Private Placement FinancingDownload PDFPrinter Friendly Version
06/10/14June 10, 2014 Conference CallDownload PDFPrinter Friendly Version
06/10/14BrainStorm Expands Pipeline with Initiation of Pre-clinical Study in AutismDownload PDFPrinter Friendly Version
06/09/14BrainStorm Cell Therapeutics Appoints Tony Fiorino, MD, PhD as Chief Executive OfficerDownload PDFPrinter Friendly Version
06/06/14First Patient Enrolled in BrainStorm's Phase II ALS Trial at Massachusetts General HospitalDownload PDFPrinter Friendly Version
06/05/14BrainStorm Hosting Conference Call to Update Shareholders on Major DevelopmentsDownload PDFPrinter Friendly Version
06/02/14Positive Interim Phase IIa ALS Data with BrainStorm's NurOwn™ Presented at Joint Congress of European NeurologyDownload PDFPrinter Friendly Version
05/29/14BrainStorm Announces Redemption of Outstanding Warrants for CashDownload PDFPrinter Friendly Version
05/27/14BrainStorm to Present Phase IIa ALS Clinical Trial Data at the Joint Congress of European NeurologyDownload PDFPrinter Friendly Version
05/19/14BrainStorm Cell Therapeutics Presenting at Multiple Upcoming ConferencesDownload PDFPrinter Friendly Version
04/28/14FDA Approves Commencement of BrainStorm's Phase II ALS Clinical Trial in U.S.Download PDFPrinter Friendly Version
04/28/14April 28, 2014 Conference Call Download PDFPrinter Friendly Version
04/25/14BrainStorm Announces Exchange of Outstanding WarrantsDownload PDFPrinter Friendly Version
04/22/14BrainStorm Hosting Conference Call to Update Shareholders on Important DevelopmentsDownload PDFPrinter Friendly Version
04/10/14BrainStorm Granted Additional US Patent for its Autologous Stem Cell TechnologyDownload PDFPrinter Friendly Version
03/25/14BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical TrialDownload PDFPrinter Friendly Version
03/24/14BrainStorm Granted Key US Patent for its Autologous Stem Cell TechnologyDownload PDFPrinter Friendly Version
03/18/14BrainStorm to Present Latest Company Developments at Regen Med Investor Day March 26 in New YorkDownload PDFPrinter Friendly Version
02/25/14BrainStorm Receives Additional $600,000 Non-Dilutive Grant from Israel’s Office of the Chief ScientistDownload PDFPrinter Friendly Version
02/04/14BrainStorm Issues Annual Letter to ShareholdersDownload PDFPrinter Friendly Version
02/03/14BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology PatentDownload PDFPrinter Friendly Version
01/30/14January 30, 2014 Conference CallDownload PDFPrinter Friendly Version
01/29/14BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn ManufacturingDownload PDFPrinter Friendly Version
01/15/14BrainStorm Hosting a Conference Call with Clinical Trial Advisors in Israel US and Brazil to Update Shareholders on Current DevelopmentsDownload PDFPrinter Friendly Version
01/13/14BrainStorm Receives United States Patent Office Notice of Allowance for its Stem Cell TechnologyDownload PDFPrinter Friendly Version
01/08/14BrainStorm Receives Notice of Allowance to Grant European Patent Covering its Stem Cells for the Treatment of CNS DiseasesDownload PDFPrinter Friendly Version
01/06/14Significant Clinical Findings in ALS Patient Treated with BrainStorm's NurOwn Featured in “Muscle and Nerve”Download PDFPrinter Friendly Version